VEGF-A and Ang-2 drive retinal vascular disease together^1-5

Start with the power of dual pathway inhibition^1,6,7

References

1. Regula JT, et al. EMBO Mol Med. 2016;8:1265–88.
2. Augustin AJ, et al. Clin Ophthalmol. 2009;3:175–82.
3. Heier JS, et al. Retina. 2021;41:1–19.
4. Joussen AM, et al. Eye (Lond). 2021;35:1305–16.
5. Larsen HO, et al. Ophth Ther. 2023;12:2253–64.
6. Heier JS, et al. Lancet. 2022;399:729–40.
7. Wykoff CC, et al. Lancet. 2022;399:741–55.
8. VABYSMO®. SmPC https://go.roche.com/Vabysmo_SmPC Accessed May 2024
9. VABYSMO®. Prescribing Information. https://www.gene.com/download/pdf/vabysmo_prescribing.pdf Accessed May 2024